0001127602-21-016115.txt : 20210510
0001127602-21-016115.hdr.sgml : 20210510
20210510174334
ACCESSION NUMBER: 0001127602-21-016115
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210507
FILED AS OF DATE: 20210510
DATE AS OF CHANGE: 20210510
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: REESE C RICHARD
CENTRAL INDEX KEY: 0001032365
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-15943
FILM NUMBER: 21908768
MAIL ADDRESS:
STREET 1: C/O IRON MOUNTAIN INC
STREET 2: 745 ATLANTIC AVE 10TH FLR
CITY: BOSTON
STATE: MA
ZIP: 02111
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CENTRAL INDEX KEY: 0001100682
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 061397316
FISCAL YEAR END: 1226
BUSINESS ADDRESS:
STREET 1: 251 BALLARDVALE ST
CITY: WILMINGTON
STATE: MA
ZIP: 01887
BUSINESS PHONE: 781-222-6000
MAIL ADDRESS:
STREET 1: 251 BALLARDVALE ST
CITY: WILMINGTON
STATE: MA
ZIP: 01887
FORMER COMPANY:
FORMER CONFORMED NAME: CHARLES RIVER LABORATORIES INTERNATIONAL INC
DATE OF NAME CHANGE: 20000605
FORMER COMPANY:
FORMER CONFORMED NAME: CHARLES RIVER LABORATORIES HOLDINGS INC
DATE OF NAME CHANGE: 19991208
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2021-05-07
0001100682
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CRL
0001032365
REESE C RICHARD
251 BALLARDVALE STREET
WILMINGTON
MA
01887
1
Common Stock
2021-05-07
4
A
0
355
0
A
63244
D
Common Stock
2021-05-07
4
A
0
234
0
A
63478
D
Stock Options (Right to Buy)
342.55
2021-05-07
4
A
0
1151
0
A
2022-05-07
2031-05-07
Common Stock
1151
1151
D
The unvested restricted stock units vest upon the earlier of 5/7/2022 or the business day prior to the Company's next annual meeting of shareholders.
The grant was made in lieu of director service fees for the term commencing May 5, 2021. The restricted stock units vest upon the earlier of 5/7/2021, or the business day prior to the Company's next annual meeting of shareholders.
The Stock Options become exercisable upon the earlier of 5/7/2022 or the business day prior to the Company's next annual meeting of shareholders.
/s/ C. Richard Reese
2021-05-10